Albert David fixes record date for final dividend of Rs 5

Albert David Limited has fixed July 30, 2026, as the record date for determining shareholder eligibility for a final dividend of Rs 5 per equity share. The dividend, recommended by the Board of Directors at its meeting on May 12, 2026, is for the financial year ended March 31, 2026, and is subject to approval by shareholders at the 87th Annual General Meeting (AGM).

The company announced that the 87th AGM will be held on Thursday, August 6, 2026, at 9:30 a.m. IST through Video Conferencing (VC) or Other Audio Visual Means (OAVM). The notice for the AGM and the Annual Report for the financial year 2025-26 will be sent electronically to members with registered email addresses. Physical copies of the report will be dispatched to members without registered email addresses.

E-Voting and Participation

Shareholders will be able to cast their votes on the business to be transacted at the AGM through a remote e-voting system or e-voting during the meeting. The detailed procedure for remote e-voting and participation via VC/OAVM will be provided in the notice of the AGM. Members attending the AGM who have not cast their vote via remote e-voting will be able to vote electronically during the meeting.

Key Dates and Details

Event	Date
AGM Date	August 6, 2026
Record Date	July 30, 2026
Board Meeting for Dividend	May 12, 2026

The company has also informed shareholders that dividend income is taxable in their hands under the Income Tax Act, 1961, and the company will deduct tax at source at the prescribed rates. Members holding shares in physical form must ensure their KYC details, including PAN and bank account details, are updated to receive dividends electronically.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.44%	-0.08%	-3.76%	-1.50%	-24.70%	+27.75%

Albert David Limited has appointed Amit Mahla as Whole-time Director and Chief Executive Officer (CEO) for a period of five years effective June 19, 2026. The Board of Directors approved the appointment based on the recommendations of the Nomination and Remuneration Committee and the Audit Committee. This leadership change is subject to the approval of shareholders at the company's upcoming 87th Annual General Meeting (AGM). The decision aims to strengthen the company's executive governance structure and leverage Mahla's extensive experience in the pharmaceutical sector.

Mahla, who has served as CEO since May 12, 2026, was inducted as an Additional Director on the Board with immediate effect from June 19, 2026. His tenure as Whole-time Director & CEO is scheduled to run until June 18, 2031, contingent upon ratification by the shareholders. The Board has fixed his remuneration for the period from June 19, 2026, to March 31, 2027. Consequently, the notice for the 87th AGM has been revised to include resolutions seeking shareholder approval for the regularisation, appointment, and remuneration fixation for Mahla. The dates for the AGM, record date for dividend payment, and book closure remain unchanged.

Profile of the Appointee

Amit Mahla, aged 52, brings over 28 years of experience to the role. He holds a degree in Science, a postgraduate degree in English Literature, and an Executive MBA from SIES, Mumbai. His career spans leadership roles at major pharmaceutical firms including Cipla, Emcure, Glenmark, Alembic, Sun Pharma, and JB Pharma. Prior to joining Albert David, he was associated with JB Pharma. He is recognized for transforming underperforming businesses into high growth engines and has led the integration of Sanzyme into JB Pharma.

Key Appointment Details

Particulars	Details
Name	Mr. Amit Mahla
DIN	11767012
Designation	Whole-time Director & CEO
Appointment Date	June 19, 2026
Term	5 years (June 19, 2026 to June 18, 2031)
Remuneration Period	June 19, 2026 to March 31, 2027
Shareholder Approval	Required at 87th AGM

The company confirmed that Mahla is not related to any director or key managerial personnel of the company and is not debarred from holding the directorship by the Securities and Exchange Board of India (SEBI) or any other authority.